BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
UBS
Daiichi Sankyo
US Department of Justice
Farmers Insurance
QuintilesIMS
Moodys
Mallinckrodt
Cerilliant
Queensland Health

Generated: January 20, 2018

DrugPatentWatch Database Preview

MONUROL Drug Profile

« Back to Dashboard

Which patents cover Monurol, and when can generic versions of Monurol launch?

Monurol is a drug marketed by Zambon Spa and is included in one NDA.

The generic ingredient in MONUROL is fosfomycin tromethamine. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosfomycin tromethamine profile page.
Summary for MONUROL
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 3
Drug Prices:see details
DailyMed Link:MONUROL at DailyMed
Drug patent expirations by year for MONUROL
Medical Subject Heading (MeSH) Categories for MONUROL

US Patents and Regulatory Information for MONUROL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zambon Spa MONUROL fosfomycin tromethamine FOR SUSPENSION;ORAL 050717-001 Dec 19, 1996 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Citi
US Department of Justice
Covington
Healthtrust
Cipla
Novartis
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot